ADC Drug Combination: How to Achieve 1+1>2

ADC Drug Combination: How to Achieve 1+1>2

Antibody-drug conjugates (ADC) are a novel type of medication that couples monoclonal antibodies, which specifically recognize cancer cell surface antigens, with cytotoxic chemotherapy drugs through specific linkers, exerting a significant tumor-killing effect. Currently, 15 ADC drugs, represented by trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd, DS-8201), have been approved globally, significantly changing the treatment landscape … Read more

Cascade-Activatable Nanoprodrug System Enhances Bladder Cancer Treatment

Cascade-Activatable Nanoprodrug System Enhances Bladder Cancer Treatment

iNature Sonochemotherapy (SCT) triggers an excessive production of reactive oxygen species (ROS) and controlled release of chemotherapeutic drugs through ultrasound, becoming a powerful cancer treatment method. However, achieving spatiotemporal controlled release of chemotherapeutic drugs during ROS generation remains a significant challenge. On December 17, 2024, a collaborative research paper titled“Cascade-Activatable Nanoprodrug System Augments Sonochemotherapy of … Read more

Challenging Intrahepatic Cholangiocarcinoma: Irreversible Electroporation Assists in Breaking the Deadlock

Challenging Intrahepatic Cholangiocarcinoma: Irreversible Electroporation Assists in Breaking the Deadlock

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer after hepatocellular carcinoma, accounting for approximately 10%-15% of primary liver cancer cases, and is rightly termed the “second-in-command” killer within the liver. Over the past 40 years, the incidence of ICC has been on the rise globally, particularly pronounced in Asia. ▲ Image source: … Read more